製薬R&Dの詳細を解き明かす、PharmaR&D Review 2025レポート

Pharma R&D Review 2025レポートでは、40年の歴史を誇る当社データベースをもとに、世界の医薬品開発パイプラインの詳細をご紹介。 企業別、治療分野別、疾患別、ターゲット別、薬剤タイプ別にトレンドを分析し、製薬R&Dの全体像をご提供します。

このレポートで得られるもの：

  • 医薬品開発の流行り廃り
  • 開発中の22,000以上の薬剤に関する豊富なデータ
  • 業界のトレンドセッターやイノベーターの分析
  • 2025年の戦略を立てるための昨シーズンの教訓
''
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.

FROM SEED
TO SCALE

From early seeds of innovation to late‑stage assets coming into bloom, this year’s analysis digs deep into where the industry is flourishing, where growth is slowing, and which therapeutic areas are bearing the richest fruit.

Grounded in robust data and fresh insight, The Pharma R&D Annual Review 2026 is an essential seasonal digest for anyone wanting to see how pharma’s garden is really growing.

EXPLORE THE CONTENT

MEET THE SPEAKERS

Headshot of Ian Lloyd.

IAN LLOYD

Senior Director for Pharmaprojects

For 33 years, Ian has been the chief author of the annual Pharma R&D Review. His data-driven insights and unique perspective are a staple in the pharmaceutical calendar. Our webinar is your opportunity to put your questions directly to Ian, and uncover new insights that could unlock your future strategy.

Headshot of Alexandra Shimmings.

ALEX SHIMMINGS

Executive Editor, Scrip

As the head of our European editorial team, Alex has covered breakthroughs in R&D across a range of therapeutic areas, including infectious diseases, cardiology, and cancer. She frequently interviews key players in the industry, keeping her finger on the pulse of the global pharma R&D landscape.

Frequently Asked Questions
The Pharma R&D Annual Review 2026 is a comprehensive analysis of the global pharmaceutical research and development pipeline, exploring how drug development is evolving across companies, therapeutic areas, technologies, and geographies at the start of 2026.
The review is designed for pharmaceutical and biotech executives, R&D leaders, strategists, investors, analysts, and anyone seeking a data-led understanding of where global drug development is flourishing — and where future growth opportunities lie.
This edition examines pipeline size and growth, development phases, leading pharma companies, therapeutic and disease focus, mechanisms of action, drug types, and regional trends. A gardening and agriculture theme is woven throughout to illustrate how innovation is planted, nurtured, and brought to harvest.
The analysis is primarily based on Pharmaprojects+ data, part of the Citeline suite, which has tracked global drug development since 1980. Clinical trial insights are supplemented using Trialtrove+, ensuring a robust, data-driven view of R&D activity.
At the start of 2026, the active global R&D pipeline comprises 22,940 drugs. While this represents a modest year-on-year decline, the report explains why this reflects data normalization rather than a loss of industry momentum.
Oncology remains the largest area of focus, although its share has begun to plateau. Significant growth is also seen in neurology, immunology, metabolic diseases, obesity, and rare diseases, highlighting a broadening of industry priorities.
Rare diseases account for a growing share of the pipeline, driven by high unmet need and regulatory incentives such as orphan drug designation. The report explores how both large pharma and smaller innovators are cultivating this space.
For the first time, biotech drugs outnumber small molecules in the pipeline. Rapid growth is seen in monoclonal antibodies, antibody drug conjugates, cell and gene therapies, RNA-based treatments, and precision targeted mechanisms.
The US continues to lead global pharma R&D, with China close behind and showing signs of maturation. The report also highlights important regional dynamics across Europe, Japan, South Korea, India, and other key markets.
Darkened Qualified calendar. Please allow all cookies to use functionality.

To enable the booking feature, please enable all cookies in your browser.